Measures to enhance angiotensin-receptor blocker prescribing efficiency in Belgium following generic losartan: impact and implications for the future-Reference-Cited by-同舟云学术

Measures to enhance angiotensin-receptor blocker prescribing efficiency in Belgium following generic losartan: impact and implications for the future

Published:2013-06-17 Issue:3 Volume:4 Page:173-181
ISSN:1759-8885
Container-title:Journal of Pharmaceutical Health Services Research
language:en
Short-container-title:Journal of Pharmaceutical Health Services Research

Author:

Simoens Steven¹,De Bruyn Kristien²,Miranda Jamilette³,Bennie Marion⁴⁵,Malmström Rickard E.⁶,Godman Brian⁷⁴⁸

Affiliation:

1. KU Leuven Department of Pharmaceutical and Pharmacological Sciences; Leuven Belgium

2. Centre for Statistics; Belgian Pharmaceutical Society; Brussels Belgium

3. Department of Healthcare Development; Public Healthcare Services Committee Administration; Stockholm County Council; Stockholm Sweden

4. Strathclyde Institute of Pharmacy and Biomedical Sciences; University of Strathclyde; Glasgow UK

5. Information Services Division; NHS National Services Scotland; Edinburgh UK

6. Department of Medicine; Clinical Pharmacology Unit; Karolinska Institutet, Karolinska University Hospital Solna; Stockholm Sweden

7. Department of Laboratory Medicine; Division of Clinical Pharmacology; Karolinska Institutet; Karolinska University Hospital Huddinge; Stockholm Sweden

8. Liverpool Health Economics Centre; University of Liverpool Management School; Liverpool UK

Funder

Karolinska Institutet

Publisher

Oxford University Press (OUP)

Subject

Pharmacology, Toxicology and Pharmaceutics (miscellaneous),Economics, Econometrics and Finance (miscellaneous)

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/jphs.12024/fullpdf

Reference68 articles.

1. Ongoing pharmaceutical reforms in France; implications for key stakeholder groups;Sermet;Appl Health Econ Health Policy,2010

2. Insight into recent reforms and initiatives in Austria; implications for key stakeholders;Godman;Expert Rev Pharmacoecon Outcomes Res,2008

3. Recent national and regional drug reforms in Sweden - implications for pharmaceutical companies in Europe;Wettermark;Pharmacoeconomics,2008

4. Enhancing the rational use of new medicines across European healthcare systems - A Position Paper;Garattini;Eur J Clin Pharmaco,2008

5. Comparing policies to enhance prescribing efficiency in Europe through increasing generic utilisation: changes seen and global implications;Godman;Expert Rev Pharmacoecon Outcomes Res,2010

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Are new models needed to optimize the utilization of new medicines to sustain healthcare systems?;Expert Review of Clinical Pharmacology;2014-12-09

2. Review of ongoing initiatives to improve prescribing efficiency in China; angiotensin receptor blockers as a case history;Expert Review of Pharmacoeconomics & Outcomes Research;2014-10-28

3. Different initiatives across Europe to enhance losartan utilization post generics: impact and implications;Frontiers in Pharmacology;2014-10-08

4. Can authorities appreciably enhance the prescribing of oral generic risperidone to conserve resources? Findings from across Europe and their implications;BMC Medicine;2014-06-13

5. Generic atypical antipsychotic drugs in Belgium: their influence and implications;Journal of Comparative Effectiveness Research;2013-11